LHV finantsportaal

Foorum Investeerimine

Börsipäev 26. oktoober

Kommentaari jätmiseks loo konto või logi sisse

  • Nädala selgroog murdus Tallinna (-0.09%) ja Riia (-0.33%) börsil punanes ning Vilnius (+0.24%) lõpetas plusspoolel. Põhinimekirjas tehti 583 tehingut kogumahus 930 tuhat eurot, millest Vilniuse börsi käive moodustas 528 tuhat eurot ning Tallinna börsi käive 316 tuhat eurot ning tehingute arvud olid vastavalt 312 ja 198.

    Enimkaubeldud aktsiana jätkas Šiaulių bankas (+1.49%) käibega 314 tuhat eurot ja tehingute arv oli 172. Järgnes Olympic Entertainment Group (0.00) käibega 72 tuhat eurot ning tehingute arv oli 29. Harju Elekter (+3.11%) aktsiaga tehti 59 tehingut kogumahus 67 tuhat eurot.

    Kõige enam tõusid SAF Tehnika (+8.64%, käive EUR 63k), Baltika (+3.32%, käive EUR 60), Skano Group (+3.27%, käive EUR 200). Suurimad langejad olid PRFoods (-4.17%, käive EUR 20), Arco Vara (-3.09%, käive EUR 4k), Grindeks (-1.23%, käive EUR 11k).

    Täna:
    Latvijas kuģniecība erakorraline aktsionäride koosolek
    Olympic Entertainment Group kolmanda kvartali tulemused

    Homme:
    Tallinna Vesi kolmanda kvartali tulemused ja tulemuste tutvustamise webinar ning Apranga, Valmieras stikla šķiedra kolmanda kvartali tulemused.
  • Päevase pausi teinud karud said eile taas jala ukse vahele, aidates tuua leevendust üleostetud sentimenti. Sessiooni põhjadest sulgusid indeksid siiski kõrgemal, jättes S&P 500, Nasdaqi ja Dow Jonesi kaotuseks -0,5%. Valdava osas päevast plussis kaubelnud Euroopa aktsiaturud liikusid koos USA börsiga madalamale, päädides Stoxx 600 indeksi jaoks -0,6% langusega.

    Kasumit võeti vaatama oodatust tugevamale konjunktuurile. Ligikaudu 7000 Saksamaa ettevõtte küsitlusel põhinev kindlustunde indeks saavutas oktoobris rekordkõrge taseme, mis näitab, et viimase aja poliitilised arengud nii kodumaal kui ka mujal Euroopas pole heidutanud väga kõrget optimistlikku meeleolu ja väljavaadet tulevikule.

    USA uute majade müük hüppas septembris 18,9% annualiseeritult 667 tuhandele, ületades analüütikute oodatud -1,1% langust 554 tuhandele. Orkaanide järgselt oodati küll müügi taastumist lõunaosariikides, kuid ootamatult tugevaks osutus müük üleriigiliselt

    USA uute majade müük (annualiseeritud, tuhat)


    Fundamentaalselt tugevamale majandusele viitab ka kestuskaupade tarne, mis kaitse- ja lennutööstust arvestamata kerkis septembris 0,7% võrreldes augustiga (oodati 0,1%), peegeldades ettevõtete aktiivsust investeeringute tegemisel. Kuna ootusi ületas tublisti ka tellimuste kasv (0,3% asemel 1,3%), saadab see signaali trendi jätkumisest neljandas kvartalis.

    USA kestuskaupade tellimused ilma kaitse- ja lennutööstuseta (mln)


    Turuosaliste tähelepanu on täna suunatud Euroopa Keskpangale, mille nõukogu peaks teatavaks tegema varade ostuprogrammi saatuse alates tuleva aasta jaanuarist. Eeldatavalt vähendatakse kuiseid ostusid poole võrra 30 miljardi euroni ning programmi hoitakse jõus kuni septembrini. Intressimäära otsuse langetavad ka Norra ja Rootsi keskpank.

    09.00 Saksamaa tarbijate kindlustunde indeks (november)
    10.30 Rootsi keskpanga intressimäära otsus
    11.00 Norra keskpanga intressimäära otsus
    11.00 Itaalia tarbijate ja ettevõtete kindlustunde indeks (oktoober)
    11.00 Eurotsooni rahapakkumise ja krediidi statistika (september)
    14.45 Euroopa Keskpanga istung
    15.30 Mario Draghi pressikonverents
    15.30 USA esmased töötu abiraha taotlused
    17.00 USA majade pooleliolevad müügitehingud (september)
    18.00 USA Kansas City FEDi töötleva tööstuse küsitlus (oktoober)
  • Saksamaa tarbijate kindlustunde indeks on novembris alanemas -0,1 punkti võrra 10,7 punktile, samas kui analüütikud ootasid püsimist 10,8 punktil. Sellele vaatamata on tegemist ajalooliselt väga kõrge tasemega.
  • Rootsi keskpank jättis intressimäära -0,5% peale, QE tuleviku üle otsustatakse detsembris

    SWEDEN'S RIKSBANK LEAVES KEY RATE UNCHANGED AT -0.500%
    RIKSBANK SEES SWEDISH GDP GROWTH AT 2.9 IN 2017, 2.9% IN 2018
    RIKSBANK PREPARED FOR FURTHER MONETARY POLICY EASING IF NEEDED
    RIKSBANK AWAITING FURTHER INFO BEFORE POSSIBLY EXTENDING QE
    RIKSBANK STILL DOESN'T SEE RATE INCREASE UNTIL MIDDLE OF 2018
  • NORGES BANK LEAVES KEY RATE UNCHANGED AT 0.50%
  • Eurotsooni majapidamistele väljastatud laenude kasv püsis septembris 2,7% peal ja väljaspool finantssektorit tegutsevatele ettevõtetele kiirenes 0,1pp võrra 2,5%le
  • Üsna ootuspärane samm aga täiendava optsiooniga vajadusel jätkata ning isegi suurendada pärast septembrit

    (1) The interest rate on the main refinancing operations and the interest rates on the marginal lending facility and the deposit facility will remain unchanged at 0.00%, 0.25% and -0.40% respectively. The Governing Council continues to expect the key ECB interest rates to remain at their present levels for an extended period of time, and well past the horizon of the net asset purchases.
    (2) As regards non-standard monetary policy measures, purchases under the asset purchase programme (APP) will continue at the current monthly pace of €60 billion until the end of December 2017. From January 2018 the net asset purchases are intended to continue at a monthly pace of €30 billion until the end of September 2018, or beyond, if necessary, and in any case until the Governing Council sees a sustained adjustment in the path of inflation consistent with its inflation aim. If the outlook becomes less favourable, or if financial conditions become inconsistent with further progress towards a sustained adjustment in the path of inflation, the Governing Council stands ready to increase the APP in terms of size and/or duration.
    (3) The Eurosystem will reinvest the principal payments from maturing securities purchased under the APP for an extended period of time after the end of its net asset purchases, and in any case for as long as necessary. This will contribute both to favourable liquidity conditions and to an appropriate monetary policy stance.
    (4) The main refinancing operations and the three-month longer-term refinancing operations will continue to be conducted as fixed rate tender procedures with full allotment for as long as necessary, and at least until the end of the last reserve maintenance period of 2019.
  • YELLEN OUT OF FED CHAIR RACE, POLITICO SAYS, CITING A SOURCE
  • Initial Claims 233K vs 235K Briefing.com consensus; Prior222K
  • Gapping up
    In reaction to strong earnings/guidance:

    MNOV +19.1%, BWLD +18.3%, TREE +12%, TWTR +9.4%, ECHO +7.1%, STM +6.7%, TER +5.7%, IRDM +5%, NVCR +5%, AEM +4.2%, INVA +4%, BGG +4%, DCM +3.6%, LKQ +3.3%, SXCP +3.3%, SAN +3.2%, GDI +2.9%, MAA +2.7%, ABEV +2.6%, RS +2.5%, PTC +2.4%, ABB +2.3%, VSH +2.3%, SRPT +2.2%, LVS +2%, SAVE +2%, ELY +1.9%, GG +1.7%, SU +1.7%, EQT +1.7%, MCK +1.7%, WLL +1.6%, FTI +1.6%, VALE +1.6%, F +1.5%, RTN +1.5%, VLO +1.5%, XRX +1.5%, SBGL +1.4%, CSLT +1.2%, FNF +1.1%, PX +1.1%, O +1%, CSII +1%, CX +1%, QSR +1%, AFL +0.9%, MO +0.9%
    Other news:
    VTGN +33.3% (announces FDA has authorized the Co to proceed, under its Investigational New Drug application, with its planned Phase 2 clinical study of AV-101
    MNOV +18.4% (announces that the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) achieved both primary endpoints)
    TRVN +17% (announces publication of the results of APOLLO-1 and APOLLO-2 at the 2017 Annual Meeting of the American Society of Anesthesiologists from positive Phase 3 trials )
    NNVC +6.3% (extended its agreement with SUNY Upstate Medical Center for further testing of its nanoviricides drug candidates against Shingles)
    QTNT +5.4% (indicated higher after Highbridge Capital discloses increased passive stake to 9.92%)
    TGTX +4.3% (announces results from the Phase 2 multicenter trial of TG-1101)
    PSTI +4% (received approval from Israel's Ministry of Health to initiate a Phase I trial studying the company's PLX-R18 cell therapy)
    AGEN +3.2% (CDC Advisory Committee on Immunization Practices voted in favor of three recommendations for the use of Shingrix containing QS-21 Stimulon for the prevention of shingles)
    VERU +2.8% (files for $50 mln mixed securities shelf offering)
    CZR +2% (LVS sympathy)
    TSRO +1.8% (receives FDA approval for VARUBI IV )
    WYNN +1.2% (LVS sympathy)
    Analyst comments:
    LEA +0.5% (upgraded to Outperform at RBC Capital Mkts)
    Gapping down
    In reaction to disappointing earnings/guidance:

    NOK -16.2%, UCTT -11.3%, NTRI -10.8%, TAL -10.8%, CELG -9.8%, MLNX -8.6%, ESND -8%, VAR -6.6%, OII -6.5%, ORLY -6.3%, ONCS -6.1%, JAKK -5.9%, XLNX -5.3%, UHS -5.2%, BCS -5.2%, ALKS -5%, RVLT -5%, POT -4.8%, NOW -4.5%, DLB -4%, SSNC -3.9%, BSX -3.7%, CA -3.5%, MC -3.5%, TSCO -3.3%, HLI -3.2% (also announces secondary offering of class A common stock by selling stockholders), CDE -2.9%, NTGR -2.8%, IART -2.8%, MMLP -2.7%, PKG -2.7%, AMGN -2.6%, DNKN -2.5%, KKR -2.5%, BUD -2.4%, FAF -2.4%, ABMD -2.3%, DB -2.2%, GNC -2.1%, ALLE -1.9%, MDP -1.9%, WPG -1.6%, BMY -1.6%, STO -1.4%, CMO -1%, VC -1%, RJF -0.9%, VRTX -0.9%, ABX -0.9%, PSA -0.8%, ICLR -0.8%
    Other news:
    ATOS -24.5% (proposes public offering of common stock)
    IDRA -21.7% (prices 33,333,334 shares at $1.50)
    VBIV -6% (commenced an underwritten public offering and a registered direct offering of its common shares )
    HCM -4.6% (prices 9,886,792 ADSs at $26.50 per share)
    CSX -4.5% (light volume; CSX authorized $1.5 billion in share repurchases; is postponing its scheduled October 30th Investor Conference to a later date)
    Analyst comments:
    PCRX -5.8% (downgraded to Sell from Neutral at Janney)
    PTCT -5.4% (downgraded to Underperform from Neutral at BofA/Merrill)
    TRVG -1.8% (downgraded to Underperform from Neutral at BofA/Merrill; downgraded to Neutral from Buy at Guggenheim)
    WWD -1.7% (downgraded to Perform from Outperform at Oppenheimer)
    GSK -1% (downgraded to Neutral from Buy at BofA/Merrill)
    LB -1% (downgraded to Neutral from Buy at Buckingham Research)

    Briefing.com
  • AMZN-lt väga võimas tulemus:

    Amazon prelim Q3 $0.52 vs ($0.01) Capital IQ Consensus Estimate; revs $43.7 bln vs $42.26 bln Capital IQ Consensus Estimate; operating income decreased 40% to $347 million vs. ($400)-300 mln guide

    Aktsia kaupleb $1045 juures, +7%

Teemade nimekirja